Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. BeOne Medicines's current 3-Year Share Buyback Ratio was -2.00%.
The historical rank and industry rank for BeOne Medicines's 3-Year Share Buyback Ratio or its related term are showing as below:
ONC'
s 3-Year Share Buyback Ratio Range Over the Past 10 Years
Min: -26.2 Med: -14.45 Max: -1.2
Current: -2
During the past 13 years, BeOne Medicines's highest 3-Year Share Buyback Ratio was -1.20%. The lowest was -26.20%. And the median was -14.45%.
ONC's 3-Year Share Buyback Ratio is ranked better than 77.71% of 1189
companies
in the Biotechnology industry
Industry Median: -11.8
vs ONC: -2.00
BeOne Medicines (NAS:ONC) 3-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
BeOne Medicines 3-Year Share Buyback Ratio Related Terms
ONC vs RVMD, MRNA, ALNY: 3-Year Share Buyback Ratio Comparison
For the Biotechnology subindustry, BeOne Medicines's 3-Year Share Buyback Ratio, along with its competitors' market caps and 3-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines 3-Year Share Buyback Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's 3-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's 3-Year Share Buyback Ratio falls into.
BeOne Medicines 3-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from three years ago to the current year. The annualized percentage change is calculated with expontential compound based on the latest four years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 3-Year Share Buyback Ratio of -2.00 mean?
BeOne Medicines (ONC) has a 3-Year Share Buyback Ratio of -2.00 as of Jun. 2026. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #265 out of 1189 companies in the Biotechnology industry, placing it in the top 22.3%.
Is BeOne Medicines' 3-Year Share Buyback Ratio too high?
BeOne Medicines' current 3-Year Share Buyback Ratio is -2.00. Based on the distribution chart, BeOne Medicines ranks #265 out of 1189 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' 3-Year Share Buyback Ratio compare to RVMD and MRNA?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #265 out of 1189 companies for 3-Year Share Buyback Ratio. This places BeOne Medicines in the top 22% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Share Buyback Ratio for a Biotechnology company?
A good 3-Year Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Share Buyback Ratio mean?
A high 3-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past three years. It is calculated as the annualized percentage change in shares outstanding from three years ago to the current year. View historical data for BeOne Medicines and its competitors. BeOne Medicines's current 3-Year Share Buyback Ratio is -2.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Fairly Valued. The stock's GF Value™ is $378.22, compared to a current price of $358.66 — trading 5.2% below its estimated fair value. The current 3-Year Share Buyback Ratio is -2.00. BeOne Medicines' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Share Buyback Ratio calculated?
3-Year Share Buyback Ratio is calculated from a company's financial statements. For BeOne Medicines (ONC), the current 3-Year Share Buyback Ratio is -2.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (ONC) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of $358.66 is trading 5.2% below its estimated GF Value™ of $378.22.
GuruFocus considers BeOne Medicines to be Fairly Valued.
Key valuation signals for ONC:
3-Year Share Buyback Ratio: -2.00
GF Value™: $378.22 vs. price of $358.66 (5.2% below fair value)
No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
80GF Score
Get the complete analysis for ONC
3-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ONC has been successfully added to your 
